Alnylam Pharmaceuticals, Inc. (ALNY)
Health Care ยท Pharmaceutical Preparations
Alnylam Pharmaceuticals, Inc. (ALNY) is listed on Nasdaq, where its shares have traded since May 28, 2004. SentiSense covers Alnylam Pharmaceuticals, Inc. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations. Yvonne Greenstreet is its chief executive officer. The company reports 2,500 employees, and its corporate website is www.alnylam.com.
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 768 institutions reported holding ALNY, with 132.6 million shares worth $39.9 billion in aggregate. The largest reported holders were Capital Group, FMR and Vanguard. Of the 5 largest reported holders, all 5 added shares during the quarter.
More on ALNY
- ALNY sentiment: whether news and social coverage of Alnylam Pharmaceuticals, Inc. leans bullish or bearish, and the stories driving it.
- ALNY ownership: all 768 reporting institutions, plus insider and congressional trades.
- ALNY financials: revenue, net income, operating margin and free cash flow by quarter and year.
SentiSense also tracks daily options readings for Alnylam Pharmaceuticals, Inc.: IV rank, put/call percentile, 25-delta skew and open-interest walls.
Frequently asked questions
What does Alnylam Pharmaceuticals, Inc. do?
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics.
What sector is ALNY in?
SentiSense classifies Alnylam Pharmaceuticals, Inc. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations.
Where does ALNY stock trade?
Alnylam Pharmaceuticals, Inc. (ALNY) is listed on Nasdaq, where its shares have traded since May 28, 2004.
Who is the CEO of Alnylam Pharmaceuticals, Inc.?
Yvonne Greenstreet is the chief executive officer of Alnylam Pharmaceuticals, Inc..